CLC Number:
| [1] von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(7): 815-833. [2] Lu J, Wood D, Ingley E, et al. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma [J]. Mol Biol Rep, 2021, 48(4): 3637-3647. [3] Andrea T, Giulio G, Giuliana L, et al. Primary dedifferentiated liposarcoma of the orbit, a rare entity: case report and review of literature [J]. Saudi J Ophthalmol, 2019, 33(3): 312-315. [4] Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft tissue sarcoma(TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial [J]. Lancet Oncol, 2017, 18(8): 1089-1103. [5] 郭曦, 庄荣源, 周宇红, 等. 化疗联合程序性细胞死亡受体1抗体和安罗替尼对晚期去分化脂肪肉瘤的疗效及其安全性 [J]. 中华医学杂志, 2022, 102(31): 2428-2434. GUO Xi, ZHUANG Rongyuan, ZHOU Yuhong, et al. Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma [J]. National Medical Journal of China, 2022, 102(31): 2428-2434. [6] Wang HY, Chu JF, Zhang P, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in chinese patients with advanced/metastatic soft tissue sarcoma [J]. Onco Targets Ther, 2020, 13: 1561-1568. doi:10.2147/OTT.S235349. [7] Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft tissue sarcoma [J]. Clin Cancer Res, 2018, 24(21): 5233-5238. [8] Sun X, Zhang R, Xu J, et al. First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: a prospective, single-arm trial [J]. Asian Pac J Trop Bio, 2022, 15(6): 266-273. [9] Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation [J]. Clin Cancer Res, 2007, 13(5): 1374-1382. [10] 王宪, 吕海茹. 超声引导经皮穿刺微波消融联合无水酒精对3~5 cm原发性肝癌的疗效及复发影响因素 [J]. 山西医药杂志, 2023, 52(4): 260-264. WANG Xian, LYU Hairu. Efficacy and recurrence factors of ultrasound-guided percutaneous microwave ablation combined with anhydrous clcohol injection for 3-5 cm primary liver cancer [J]. Shanxi Medical Journal, 2023, 52(4): 260-264. [11] Meng L, Wei Y, Xiao Y. Chemo-immunoablation of solid tumors: a new concept in tumor ablation[J]. Front Immunol, 2023, 13: 1057535. doi:10.3389/fimmu.2022.1057535. [12] 李文东, 郭晓笛, 陈京龙, 等. CT引导下经皮无水乙醇注射联合射频消融治疗高危部位原发性肝癌 [J]. 中国微创外科杂志, 2021, 21(7): 605-609. LI Wendong, GUO Xiaodi, CHEN Jinglong, et al. CT-guided percutaneous ethanol injection combined with radioferquency ablation for treatment of primary liver cancer in high-risk locations[J]. Chinese Journal of Minimally Invasive Surgery, 2021, 21(7): 605-609. [13] 韩明勇, 于晓黎, 曾放平, 等. CT引导经皮肺穿刺肿瘤内化疗技术流程 [J]. 山东大学学报(医学版), 2023, 61(11): 11-19. HAN Mingyong, YU Xiaoli, ZENG Fangping, et al. Technical procedure of CT-guided intratumoral chemotherapy for lung tumor [J]. Journal of Shandong University(Health Sciences), 2023, 61(11): 11-19. [14] León-Salas B, Hernández-Yumar A, Infante-Ventura D, et al. Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies: a systematic review, meta-analysis and economic evaluation [J]. Endocrinol Diabetes Nutr(Engl Ed), 2023, 70(9): 572-583. |
| [1] | . [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 110-112. |
| [2] | LI Yang, HE Chuang, CHEN Yuxiao, YANG Li, LI Liangshan, LI Tingyuan, HUANG Xuequan. CT-guided interstitia 125I seed implantation in the treatment of long bone metastasis: a primary clinic study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 50-54. |
| [3] | TIAN Siqi, LIU Riqiang, YANG Ning, WEI Wei, YANG Huawei. Effect of expression of ribosomal protein S6 Kinase 4 variants on the proliferation of breast cancer cell MDA-MB-231 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 32-36. |
| [4] | HAN Ming-yong,LIU Qi,TANG Bu-jian,DENG Yan,CAO Ming-feng. In vivo vaccine effect and tumorigenicity of human breast carcinoma cells transfered by interleukin-18 gene [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(7): 714-717. |
| [5] |
ZHANG Hao， HAN Junqing， YANG Zhe， MU Xueru， ZHAO Hongli， WANG Peng . Postoperative concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(04): 105-108. |
| [6] | HUANG Naibang, DA Peng, LU Jun, WU Hao. Applications of different mandibulotomy approaches to the resection of pharyngeal region tumors [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 79-82. |
|
||
